; and (iv) the impact of the Bureau’s work on patient affordability and access to prescription drugs. (B) Recommendations for such legislation and administrative action as the Bureau determines appropriate. (C) A copy of each report submitted by drug manufacturers as required under section 3. (D) Other items that the Bureau determines appropriate. (d) Funding There are appropriated, from amounts in the Treasury not otherwise appropriated, $50,000,000 for fiscal year 2020 and each subsequent fiscal year to carry out the activities of the Bureau. Amounts appropriated under the preceding sentence shall remain available until expended. 3. Prescription drug consumer price protections (a) Review of prices (1) In general The Bureau shall conduct reviews of the prices of prescription drugs to ensure that the wholesale acquisition cost of each such drug is appropriate. (2) Information on prescription drugs approved as of enactment (A) Manufacturer submission With respect to any prescription drug that, as of the date of enactment of this Act, has in effect an application approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) or section 351 of the Public Health Service Act ( 42 U.S.C. 262 ), each manufacturer, not later than 180 days after such date of enactment, shall provide to the Bureau the following information: (i) The name of the prescription drug. (ii) A description of the prescription drug and its approved indications. (iii) The number of individuals in the United States and globally for which such prescription drug is clinically indicated. (iv) A list of patents that claim the prescription drug, a use of the prescription drug, a form of the prescription drug, a method of use of the prescription drug, or a method of manufacture of the prescription drug. (v) A list of government-granted exclusivities that prohibit the submission or approval of a prescription drug and the date that each such government-granted exclusivity was granted. (vi) The date on which the prescription drug was